Last reviewed 2026-04-23 · How we verify

ROVALCYTE

ROVALCYTE is an autologous T-cell therapy that expands and reinfuses a patient's own T cells to enhance anti-tumor immune response.

ROVALCYTE is an autologous T-cell therapy that expands and reinfuses a patient's own T cells to enhance anti-tumor immune response. Used for Metastatic melanoma or other solid tumors (investigational).

At a glance

Mechanism of action

ROVALCYTE involves ex vivo expansion of autologous T lymphocytes derived from the patient, which are then reinfused to boost cellular immunity against cancer. The mechanism leverages the patient's own immune system by amplifying T-cell populations capable of recognizing and eliminating malignant cells. This approach is designed to provide a personalized immunotherapeutic treatment with reduced risk of graft-versus-host disease compared to allogeneic cell therapies.

Approved indications

• Metastatic melanoma or other solid tumors (investigational)

Common side effects

• Cytokine release syndrome
• Fever
• Fatigue
• Infusion-related reactions

Key clinical trials

• Effectiveness of an Immune-guided Cytomegalovirus Infection Preventive Strategy Compared to a Universal Prophylactic Strategy in Renal Transplant Patients (PHASE3)
• Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• ROVALCYTE CI brief — competitive landscape report
• ROVALCYTE updates RSS · CI watch RSS
• University Hospital, Rouen portfolio CI